.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,420,319

« Back to Dashboard
Patent 5,420,319 protects ELOXATIN and is included in two NDAs. There have been four Paragraph IV challenges on Eloxatin. There are six tentative approvals for the compound protected by this patent. Additional details are available via the generic ingredient links below.

Protection for ELOXATIN has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has five patent family members in four countries.

Summary for Patent: 5,420,319

Title: Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and process of preparing same
Abstract:Disclosed is cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex having high optical purity and no toxicity and exhibiting anticancer performance, as shown in the below Formula. Cis-oxalato(trans-1-1,2-cyclohexanediamine) Pt(II) complex of the invention possesses high optical purity or 99.94% or more e.e. and a melting point of 198.3.degree. to 199.7.degree. C. The complex is synthesized employing as starting material trans-1-1,2-cyclohexamediamine or a derivative of the trans-1-1,2-cyclohexanediamine optically resoluted by means of a high performance liquid chromatography. ##STR1##
Inventor(s): Okamoto; Koji (Kanagawa, JP), Nakanishi; Chihiro (Kanagawa, JP), Taniuchi; Junichi (Kanagawa, JP), Ohnishi; Junji (Kanagawa, JP), Komoda; Yasunobu (Kanagawa, JP)
Assignee: Tanaka Kikinzoku Kogyo K.K. (JP)
Application Number:08/117,892
Patent Claim Types:
see list of patent claims
Compound; Process;

Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759-001Jan 31, 2005RXYes5,420,319*PED► subscribeY
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759-002Jan 31, 2005RXYes5,420,319*PED► subscribeY
Sanofi Aventis Us
ELOXATIN
oxaliplatin
INJECTABLE;IV (INFUSION)021759-003Nov 17, 2006DISCNNo5,420,319*PED► subscribeY
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 5,420,319

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan5-142824May 21, 1993

International Patent Family for Patent: 5,420,319

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Germany69331048► subscribe
European Patent Office0625523► subscribe
Spain2167328► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc